Apabetalone Fares Well in Early Clinical Trial

Apabetalone Fares Well in Early Clinical Trial

305538

Apabetalone Fares Well in Early Clinical Trial

Apabetalone (RVX-208), Resverlogix‘s experimental treatment for pulmonary arterial hypertension (PAH), was well-tolerated in a small clinical trial, the company announced. The trial met its primary goal of adding apabetalone to standard care to improve pulmonary vascular resistance (PVR), a measure that reflects the internal resistance to blood flow within the pulmonary arteries. “The study successfully achieved its primary objective of confirming the feasibility of the clinical study design and demonstrated encouraging results of apabetalone treatment…

You must be logged in to read/download the full post.